| Final Director's Interest Notice - MD | Nov 5, 2026 | Ownership change notice | ASX |
|---|
| Dimerix Quarterly Activities Report and Appendix 4C | Oct 28, 2026 | Quarterly report | ASX |
|---|
| Dimerix Quarterly Activities Report and Appendix 4C | Oct 28, 2026 | Quarterly report | ASX |
|---|
| New Data Supports Biological Rationale for DMX-200 in FSGS | Oct 22, 2026 | Other filings | ASX |
|---|
| 2026 AGM Notice of Meeting, Letter of Access and Proxy Form | Oct 21, 2026 | Meeting notice | ASX |
|---|
| Dimerix Announces Board Chair Transition | Oct 18, 2026 | Management or board change | ASX |
|---|
| DMX-200 First 100 Patients Complete Phase 3 Trial Treatment | Oct 15, 2026 | Operations update | ASX |
|---|
| Dimerix at Canaccord Drug & Device and Ignite Conferences | Oct 11, 2026 | Operations update | ASX |
|---|
| First Patient Reaches Four Years in DMX-200 Clinical Program | Oct 4, 2026 | Other filings | ASX |
|---|
| Notification regarding unquoted securities - DXB | Sep 28, 2026 | Other filings | ASX |
|---|
| Notification of 2026 Annual General Meeting Date | Sep 25, 2026 | Meeting notice | ASX |
|---|
| Dimerix Draws Down A$17M Under Non-Dilutive Funding Facility | Sep 22, 2026 | Financing | ASX |
|---|
| Dimerix Presents at ASX SMIDcaps Conference 2026 | Sep 22, 2026 | Other filings | ASX |
|---|
| Waiver of Listing Rule 10.1 Granted | Sep 22, 2026 | Other filings | ASX |
|---|
| Dimerix Presents at E&P Healthcare Conference 2026 | Sep 15, 2026 | Other filings | ASX |
|---|
| Dimerix DMX-652 Granted Mexican Composition of Matter Patent | Sep 13, 2026 | Other filings | ASX |
|---|
| Dimerix Investor Presentation | Sep 6, 2026 | Other filings | ASX |
|---|
| S&P DJI Announces September 2026 Quarterly Rebalance | Sep 4, 2026 | Other filings | ASX |
|---|
| Dimerix Secures A$34 Million Non-Dilutive Funding Facility | Sep 3, 2026 | Financing | ASX |
|---|
| Trading Halt | Sep 1, 2026 | Trading halt or suspension | ASX |
|---|
| Appendix 4E and 2026 Annual Report | Aug 26, 2026 | Annual report | ASX |
|---|
| Appendix 4G and Corporate Governance Statement | Aug 26, 2026 | Other filings | ASX |
|---|
| Dimerix Receives US$10M Upfront Payment from Everest | Aug 19, 2026 | Other filings | ASX |
|---|
| Dimerix Assumes Sponsorship of US IND for New Asset DMX-652 | Aug 16, 2026 | Other filings | ASX |
|---|
| Dimerix Presents at Bioshares Summit 2026 | Aug 5, 2026 | Other filings | ASX |
|---|
| Dimerix Quarterly Activities Report and Appendix 4C | Jul 29, 2026 | Quarterly report | ASX |
|---|
| US Patent Granted for Dimerix New Asset DMX-652 | Jul 22, 2026 | Other filings | ASX |
|---|
| Dimerix Expands Pipeline with Acquisition of Phase 2 Asset | Jul 16, 2026 | Acquisition or disposal | ASX |
|---|
| Dimerix Non-Dilutive Funding Builds Pipeline, Boosts Runway | Jul 16, 2026 | Financing | ASX |
|---|
| DMX-200 Available To Patients Via Post-Trial Access Pathways | Jul 8, 2026 | Operations update | ASX |
|---|
| Dimerix Licenses DMX200 to Everest for China and Asia Region | Jun 15, 2026 | Other filings | ASX |
|---|
| Dimerix Quarterly Activities Report and Appendix 4C | Apr 29, 2026 | Quarterly report | ASX |
|---|
| ACTION3 Statistical Review Complete | Apr 27, 2026 | Other filings | ASX |
|---|
| Dimerix to Conduct Review of ACTION3 Statistical Assumptions | Mar 15, 2026 | Other filings | ASX |
|---|
| Dimerix Phase 3 Trial Last Patient Receives First Dose | Mar 9, 2026 | Operations update | ASX |
|---|
| Appendix 4D and Half Year Financial Report | Feb 25, 2026 | Interim report | ASX |
|---|
| Quarterly Appendix 4C and Activities Report | Jan 28, 2026 | Quarterly report | ASX |
|---|
| BioMarin to acquire Dimerix US Partner, Amicus Therapeutics | Dec 21, 2025 | Acquisition or disposal | ASX |
|---|
| DMX-200 ACTION3 Phase 3 Trial Completes Recruitment | Dec 14, 2025 | Operations update | ASX |
|---|
| Successful Completion of Planned IDMC Review | Nov 18, 2025 | Other filings | ASX |
|---|
| Successful PARASOL Collaboration Data Analysis Outcome | Oct 7, 2025 | Other filings | ASX |
|---|
| DMX-200 receives Orphan Drug Designation in Japan | Sep 29, 2025 | Other filings | ASX |
|---|
| Appendix 4E and 2025 Annual Report | Aug 27, 2025 | Annual report | ASX |
|---|
| Dimerix receives 1st Development Milestone payment from FUSO | Jun 29, 2025 | Other filings | ASX |
|---|
| ACTION3 Clinical Trial Milestone Recruitment Update | Jun 12, 2025 | Other filings | ASX |
|---|
| 1st ACTION3 site in Japan activated and milestone triggered | May 29, 2025 | Other filings | ASX |
|---|
| Successful planned IDMC review of ACTION3 trial | May 21, 2025 | Other filings | ASX |
|---|
| Dimerix receives initial upfront payment from Amicus | May 5, 2025 | Other filings | ASX |
|---|
| Investor Webinar and Presentation | Apr 30, 2025 | Other filings | ASX |
|---|
| Dimerix Licenses DMX-200 in the US | Apr 30, 2025 | Other filings | ASX |
|---|
| Trading Halt | Apr 28, 2025 | Trading halt or suspension | ASX |
|---|
| FDA confirms Proteinuria as Primary Endpoint for US approval | Apr 27, 2025 | Operations update | ASX |
|---|
| S&P DJI Announces March 2025 Quarterly Rebalance | Mar 7, 2025 | Other filings | ASX |
|---|
| Dimerix receives initial upfront payment from FUSO | Mar 3, 2025 | Acquisition or disposal | ASX |
|---|
| Half-Year Financial Report & Appendix 4D - 31 December 2024 | Feb 24, 2025 | Interim report | ASX |
|---|
| First Paediatric Patient Recruited for ACTION3 | Jan 15, 2025 | Other filings | ASX |
|---|
| Dimerix enters Development and License Agreement for Japan | Jan 6, 2025 | Other filings | ASX |
|---|
| DMX-200 ACTION3 Phase 3 Trial Part 2 Recruitment Complete | Dec 29, 2024 | Other filings | ASX |
|---|
| Dimerix Receives $7.9M R&D Tax Incentive Rebate | Nov 14, 2024 | Other filings | ASX |
|---|
| NEPTUNE Study Network to Enhance Phase 3 Recruitment in US | Oct 31, 2024 | Other filings | ASX |
|---|
| Project PARASOL Update & Medical Advisory Board Appointment | Oct 27, 2024 | Operations update | ASX |
|---|
| ACTION3 Trial Recruitment and Multiregion Trial Site Update | Sep 15, 2024 | Operations update | ASX |
|---|
| First Paediatric Site Activated and Trial Update | Sep 11, 2024 | Other filings | ASX |
|---|
| First patient enters into Open Label Extension study | Sep 10, 2024 | Other filings | ASX |
|---|
| Preliminary Final Report | Aug 28, 2024 | Results | ASX |
|---|
| Adolescent Recruitment into ACTION3 Clinical Trial | Jul 3, 2024 | Other filings | ASX |
|---|
| Dimerix and Taiba enter into License Agreement for DMX-200 | May 26, 2024 | Other filings | ASX |
|---|
| Dimerix Receives PIP Approval from the UK MHRA | Apr 30, 2024 | Other filings | ASX |
|---|
| Dimerix Completes $20M Placement | Mar 11, 2024 | Financing | ASX |
|---|
| Dimerix Successfully Passes Efficacy Interim Analysis | Mar 10, 2024 | Operations update | ASX |
|---|
| PH3 Data Collection Complete for First Interim Analysis | Feb 26, 2024 | Other filings | ASX |
|---|
| Half-Year Financial Report & Appendix 4D - 31 December 2023 | Feb 25, 2024 | Interim report | ASX |
|---|
| ACTION3 IND Approved in China | Nov 27, 2023 | Operations update | ASX |
|---|
| Dimerix Receives Initial Upfront Payment from Advanz Pharma | Nov 5, 2023 | Other filings | ASX |
|---|
| Dimerix Announces License Agreement for EU, Canada, ANZ | Oct 4, 2023 | Other filings | ASX |
|---|
| FDA Approves Qytovra Brand Name | Sep 24, 2023 | Operations update | ASX |
|---|
| Regulatory Approval received in Malaysia for ACTION3 Study | Sep 21, 2023 | Operations update | ASX |
|---|
| Dimerix Receives $8.9M R&D Tax Incentive Rebate | Sep 12, 2023 | Other filings | ASX |
|---|
| Successful Completion of 2nd DSMB Review of FSGS Trial | Aug 7, 2023 | Other filings | ASX |
|---|
| DMX-200 FSGS PH3 Kidney Trial Part 1 Outcome set for Q1 CY24 | Jul 23, 2023 | Other filings | ASX |
|---|
| Approval received for Paediatric Investigation Plan from EMA | Jul 4, 2023 | Legal or regulatory action | ASX |
|---|
| Dimerix confirms Phase 3 study design appropriate for China | Jul 2, 2023 | Other filings | ASX |
|---|
| Prospectus | Jun 26, 2023 | Offer document | ASX |
|---|
| Dimerix Announces Update on Successful Capital Raise | Jun 5, 2023 | Other filings | ASX |
|---|
| Rights Issue Prospectus | May 4, 2023 | Financing | ASX |
|---|
| Reinstatement to Official Quotation | May 3, 2023 | Trading halt or suspension | ASX |
|---|
| Entitlement offer and Convertible Note to raise $12 million | May 3, 2023 | Financing | ASX |
|---|
| Voluntary Suspension | May 2, 2023 | Trading halt or suspension | ASX |
|---|
| Half-Year Financial Report & Appendix 4D - 31 December 2022 | Feb 26, 2023 | Interim report | ASX |
|---|
| DXB to Receive $2.8m in Prepayment of R&D Tax Incentive | Feb 16, 2023 | Other filings | ASX |
|---|
| Successful Completion of DSMB Review of Phase 3 FSGS Trial | Feb 8, 2023 | Other filings | ASX |
|---|
| FDA Confirms Inclusion of Paediatrics in ACTION3 Study | Jan 11, 2023 | Other filings | ASX |
|---|
| DMX-200 FSGS Phase 3 Trial Part 1 Recruitment Achieved | Dec 14, 2022 | Other filings | ASX |
|---|
| CLARITY 2.0 COVID-19 Study Outcome | Dec 12, 2022 | Other filings | ASX |
|---|
| Chair address and CEO presentation to AGM | Nov 28, 2022 | Other filings | ASX |
|---|
| Dimerix Receives A$6.0M R&D Tax Incentive Rebate | Oct 24, 2022 | Other filings | ASX |
|---|
| Appendix 4E and 2022 Annual Report | Aug 28, 2022 | Annual report | ASX |
|---|
| CLARITY 2.0 COVID-19 Study Concludes Recruitment | Aug 17, 2022 | Other filings | ASX |
|---|
| New Patent Family Application for DMX-700 | Aug 8, 2022 | Other filings | ASX |
|---|
| DMX-700 Study Shows Significant 80% Reduction in Lung Injury | Jul 3, 2022 | Other filings | ASX |
|---|
| REMAP-CAP COVID-19 Study Analysis Update | Jun 26, 2022 | Other filings | ASX |
|---|
| New Clinical Trial for DMX-200 in Diabetic Kidney Disease | Jun 6, 2022 | Other filings | ASX |
|---|
| Phase 3 FSGS Kidney Trial First Patient Recruited | May 30, 2022 | Other filings | ASX |
|---|
| Dimerix presentation at Bioshares Biotech Summit | May 11, 2022 | Other filings | ASX |
|---|
| FDA IND Approval for Phase 3 Study of DMX-200 in FSGS | May 8, 2022 | Other filings | ASX |
|---|
| Dimerix Receives A$3.7M R&D Tax Incentive Rebate | Mar 28, 2022 | Other filings | ASX |
|---|
| DSMB Change to REMAP-CAP COVID-19 Study | Feb 27, 2022 | Other filings | ASX |
|---|
| Half-Year Financial Report & Appendix 4D - 31 December 2021 | Feb 23, 2022 | Interim report | ASX |
|---|
| First Regulatory Approval in Europe for DMX-200 FSGS Study | Feb 1, 2022 | Other filings | ASX |
|---|
| Patients Dosed in DMX-200 COVID-19 Phase 3 Study in India | Jan 10, 2022 | Other filings | ASX |
|---|
| Ethics Approval in Australia for Phase 3 COVID-19 Study | Dec 22, 2021 | Other filings | ASX |
|---|
| DSMB Recommends Continuation of Ph3 COVID-19 Study in Europe | Dec 16, 2021 | Other filings | ASX |
|---|
| Pause in Trading | Dec 15, 2021 | Trading halt or suspension | ASX |
|---|
| First Approvals Received for Start of Phase 3 FSGS Trial | Oct 20, 2021 | Other filings | ASX |
|---|
| Phase 3 DMX-200 COVID-19 Study Expands into Australia | Oct 14, 2021 | Other filings | ASX |
|---|
| Dimerix Closes SPP Oversubscribed | Sep 30, 2021 | Other filings | ASX |
|---|
| DMX-200 CLARITY COVID-19 Study Approval in India | Sep 24, 2021 | Other filings | ASX |
|---|
| Phase 3 Study in FSGS Kidney Patients Commences | Aug 24, 2021 | Other filings | ASX |
|---|
| SPP and Options Prospectus | Aug 23, 2021 | Offer document | ASX |
|---|
| Response to ASX Query | Aug 19, 2021 | Explanation request | ASX |
|---|
| Successful $20m Placement to Fund Phase 3 Trials | Aug 15, 2021 | Financing | ASX |
|---|
| DMX-200 COVID-19 Study Opens More Sites in Europe and UK | Aug 1, 2021 | Other filings | ASX |
|---|
| FDA Confirms Phase 3 Study Design in FSGS Kidney Disease | Jul 18, 2021 | Other filings | ASX |
|---|
| Dimerix Receives Innovation Passport and ILAP Designation | Jun 6, 2021 | Other filings | ASX |
|---|
| Dimerix Confirms Phase 3 FSGS Study Design With EMA | Jun 3, 2021 | Other filings | ASX |
|---|
| DMX-200 Remains Eligible for Accelerated Approval | May 27, 2021 | Other filings | ASX |
|---|
| COVID-19 Study Recruits Multiple Patients in Europe | Apr 22, 2021 | Other filings | ASX |
|---|
| Major Shareholder Loan for $5 Million | Mar 29, 2021 | Other filings | ASX |
|---|
| Clinical Study in Patients with COVID-19 Progresses | Mar 24, 2021 | Other filings | ASX |
|---|
| DMX-200 Competitive Position Further Enhanced | Mar 23, 2021 | Other filings | ASX |
|---|
| CLARITY 2.0 Study Progresses In Patients With COVID-19 | Mar 9, 2021 | Other filings | ASX |
|---|
| Appendix 4D and Interim Financial Report | Feb 21, 2021 | Interim report | ASX |
|---|
| Dimerix Plans for Next Study in Diabetic Kidney Disease | Jan 27, 2021 | Other filings | ASX |
|---|
| Second Study to Include DMX-200 in COVID-19 Patients | Nov 29, 2020 | Other filings | ASX |
|---|
| ARDS in COVID-19 Patients Protocol Published | Nov 8, 2020 | Other filings | ASX |
|---|
| Positive Additional Data to Support DMX-200 Development | Oct 26, 2020 | Other filings | ASX |
|---|
| Receipt of R&D Tax Incentive | Oct 20, 2020 | Other filings | ASX |
|---|
| DMX-700 Data Demonstrates Effect on Key COPD Receptors | Oct 6, 2020 | Other filings | ASX |
|---|
| Positive Top-Line Results in DKD Phase 2 Clinical Study | Sep 13, 2020 | Other filings | ASX |
|---|
| Dimerix Awarded $1 Million MRFF Funding | Sep 2, 2020 | Other filings | ASX |
|---|
| Positive Top-Line Results in FSGS Phase 2a Clinical Study | Jul 28, 2020 | Other filings | ASX |
|---|
| Last Patient Completes Dosing in DKD Phase 2 Clinical Study | Jul 23, 2020 | Other filings | ASX |
|---|
| Dimerix Completes $5.8m Placement | Jun 22, 2020 | Financing | ASX |
|---|
| Last Patient Completes Dosing in FSGS Phase 2 Clinical Study | Jun 16, 2020 | Other filings | ASX |
|---|
| Global REMAP-CAP Platform Trial Protocol To Include DMX-200 | Jun 3, 2020 | Other filings | ASX |
|---|
| R&D Tax Incentive Facility | Apr 2, 2020 | Other filings | ASX |
|---|
| DMX-200 Treatment Continued Under TGA Special Access Scheme | Mar 2, 2020 | Other filings | ASX |
|---|
| Half Yearly Report and Accounts | Feb 18, 2020 | Interim report | ASX |
|---|
| Quarterly Commentary & Appendix 4C | Jan 20, 2020 | Quarterly report | ASX |
|---|
| DMX-200 Clinical Trial Update | Jan 6, 2020 | Other filings | ASX |
|---|
| Dimerix Completes $2.5m Placement | Dec 2, 2019 | Financing | ASX |
|---|
| Dimerix Holds Pre-IND Meeting on DMX-200 With FDA | Nov 24, 2019 | Other filings | ASX |
|---|
| New Drug Pipeline Candidate DMX-700 & Company Update | Oct 9, 2019 | Other filings | ASX |
|---|
| DMX-200 Phase 2 Clinical Study in DKD Completes Recruitment | Sep 25, 2019 | Other filings | ASX |
|---|
| DMX-200 Phase 2 Clinical Trial in FSGS Fully Recruited | Jul 9, 2019 | Other filings | ASX |
|---|
| DMX-200 Clinical Update | Jun 25, 2019 | Other filings | ASX |
|---|
| Dimerix Signs Licence Agreement for Receptor-HIT Technology | Jun 23, 2019 | Other filings | ASX |
|---|
| DMX-200 Manufacturing Update | May 26, 2019 | Other filings | ASX |
|---|
| Appendix 4C - quarterly | Apr 26, 2019 | Quarterly report | ASX |
|---|
| Appendix 4C and Quarterly Highlights | Jan 30, 2019 | Quarterly report | ASX |
|---|
| Dimerix Receives R&D Tax Cash Rebate Totalling $1.07m | Dec 19, 2018 | Other filings | ASX |
|---|
| 1st Patient Dosed in DMX-200 Clinical Trial for FSGS | Nov 21, 2018 | Other filings | ASX |
|---|
| DXB Receives Orphan Drug Designation in EU | Nov 20, 2018 | Other filings | ASX |
|---|
| FIRST PATIENT DOSED IN DMX-200 CLINICAL TRIAL | Nov 19, 2018 | Other filings | ASX |
|---|
| EXECUTIVE TEAM BOLSTERED THROUGH CEO & MD APPOINTMENT | Aug 26, 2018 | Other filings | ASX |
|---|
| Quarterly Review & Appendix 4C | Jul 31, 2018 | Quarterly report | ASX |
|---|
| Ethics Approval Received Appendix 3B and S.708A Notice | Jul 18, 2018 | Financing | ASX |
|---|
| Further US patent allowed for DMX-200 | Jul 1, 2018 | Other filings | ASX |
|---|
| Dual Phase 2 trials launched for CKD | May 14, 2018 | Other filings | ASX |
|---|
| Westar Capital Retained as Corporate Advisors | Apr 12, 2018 | Other filings | ASX |
|---|
| CMO Appointment and Clinical Trials Update | Mar 26, 2018 | Other filings | ASX |
|---|
| Half Year Report and Financial Statements | Feb 26, 2018 | Interim report | ASX |
|---|
| Oversubscribed Placement to Raise a Further $4.5m | Feb 20, 2018 | Financing | ASX |
|---|
| Quarterly Review and Appendix 4C | Jan 29, 2018 | Quarterly report | ASX |
|---|
| Results of Entitlement Offer | Jan 23, 2018 | Financing | ASX |
|---|
| DMX-200 Dosage Optimisation Study Successfully Completed | Jan 7, 2018 | Other filings | ASX |
|---|
| Proteomics partnership to improve treatment of CKD | Dec 13, 2017 | Other filings | ASX |
|---|
| Entitlement Offer Booklet | Dec 5, 2017 | Financing | ASX |
|---|
| Entitlement Offer to raise $5.5 million | Dec 5, 2017 | Financing | ASX |
|---|
| Suspension from Official Quotation | Dec 4, 2017 | Trading halt or suspension | ASX |
|---|
| Dimerix Phase 2a Subgroup Analysis Results | Nov 1, 2017 | Other filings | ASX |
|---|
| Ethics Committee Approval for Pharmacokinetic Trial | Oct 23, 2017 | Other filings | ASX |
|---|
| Dimerix Receives $545k R&D Tax Refund | Oct 17, 2017 | Other filings | ASX |
|---|
| Notice of Annual General Meeting/Proxy Form | Sep 12, 2017 | Meeting notice | ASX |
|---|
| DMX-200 tablet manufacture and human study timeline | Sep 4, 2017 | Other filings | ASX |
|---|
| Positive Results from Phase 2a Trial of DMX-200 | Jul 12, 2017 | Other filings | ASX |
|---|
| Research Validates Relevance of DMX Receptor-HIT Technology | Jun 12, 2017 | Other filings | ASX |
|---|
| Investor Update | Apr 10, 2017 | Other filings | ASX |
|---|
| Receipt of $420k Research & Development Tax Refund | Mar 21, 2017 | Other filings | ASX |
|---|
| Corporate Presentation | Feb 13, 2017 | Other filings | ASX |
|---|
| Key Patent Allowed in Japan | Jan 30, 2017 | Other filings | ASX |
|---|
| Dimerix Raises $2 million to Advance Clinical Program | Jan 24, 2017 | Other filings | ASX |
|---|
| Recruitment of Part A of Phase 2 Trial of DMX-200 Completed | Dec 5, 2016 | Other filings | ASX |
|---|
| Appointment of Chief Executive Officer | Nov 6, 2016 | Management or board change | ASX |
|---|
| Update presentation - interim data | Oct 11, 2016 | Other filings | ASX |
|---|
| Positive interim analysis of DMX-200 phase II data | Oct 3, 2016 | Other filings | ASX |
|---|
| Appendix 4E | Aug 24, 2016 | Results | ASX |
|---|
| Response to ASX Price and Volume Query | Aug 15, 2016 | Explanation request | ASX |
|---|
| Outcomes of DMX-200 pre-IND meeting with the FDA | Aug 1, 2016 | Other filings | ASX |
|---|
| Update for NASH Pre-Clinical Program | Jul 28, 2016 | Other filings | ASX |
|---|